UBC31 Antibody

What is UBC31/USP31 and why is it important in research?

UBC31, more commonly known as USP31 (Ubiquitin-Specific Peptidase 31), belongs to the deubiquitinating enzyme family that plays crucial roles in protein regulation through the removal of ubiquitin from proteins. Like other ubiquitin system proteins such as UbcH10, USP31 may have significant roles in cellular regulation and potentially in disease processes including tumorigenesis. The UbcH10 gene, for example, is located at 20q13.1, a genome region known to be amplified in diverse tumors . Similarly, understanding USP31's function requires specific antibodies that allow researchers to detect, quantify, and localize this protein in experimental systems, making anti-USP31 antibodies essential tools for both basic science and translational research.

What types of antibodies are available for USP31 detection?

Researchers have access to both polyclonal and monoclonal antibodies for USP31 detection. Polyclonal antibodies, such as rabbit polyclonal anti-USP31 antibody, recognize multiple epitopes on the USP31 protein, potentially providing higher sensitivity but with some variability between lots . Monoclonal antibodies offer high specificity for a single epitope, ensuring consistent results between experiments. For example, hybridomas producing monoclonal antibodies (such as those developed for other proteins like UbcH10) typically undergo rigorous characterization for titer, affinity, concentration, class, and subclass to ensure reliability . When selecting an antibody, researchers should consider the intended application and required specificity.

What applications are USP31 antibodies validated for?

USP31 antibodies undergo validation for specific applications to ensure reliability in experimental settings. Typically, these antibodies are validated for immunohistochemistry (IHC), immunocytochemistry/immunofluorescence (ICC-IF), and Western blotting (WB) . The validation process involves testing the antibody's performance in each application to confirm specificity, sensitivity, and reproducibility. For instance, antibodies against similar proteins have been validated through Western blot analysis using anti-His polyclonal antibody to confirm recognition of the predicted protein band . This rigorous validation ensures researchers can confidently use these antibodies, knowing they will provide accurate and reproducible results across different experimental conditions.

How should I design multicolor flow cytometry experiments involving USP31 antibodies?

When designing multicolor flow cytometry experiments that include USP31 antibodies, researchers must consider several critical factors for optimal results:

• Fluorochrome selection should be based on USP31 expression levels:

  • For high-density antigens: use low brightness index fluorophores

  • For mid-range density antigens: use bright/moderate index fluorophores

  • For low-density antigens: use bright/very bright index fluorophores

• For experimental design involving 3-4 colors, choose fluorochromes that minimize spectral overlap. For example, combine FITC, APC, and Pacific Blue which are excited by different lasers (blue, red, and violet) to minimize compensation requirements .

• For 5-8 color panels including USP31, expect higher degrees of compensation when adding fluorochromes like PE, PE-Cy5, PE-Cy5.5, PE-Cy7, and APC-Cy7 .

• Always include proper controls:

  • Single-color compensation tubes using compensation beads

  • Fluorescence Minus One (FMO) controls to establish accurate gating boundaries

  • Isotype controls when measuring activation markers

This approach helps establish proper gating strategies and ensures accurate data interpretation in complex multicolor panels involving USP31 detection.

How can I validate the specificity of my USP31 antibody?

Validating the specificity of USP31 antibodies is crucial for ensuring reliable experimental results. A comprehensive validation approach should include:

• Western blot analysis: Confirm the antibody detects a protein of the expected molecular weight in relevant samples. Include positive and negative control tissues/cell lines to verify specificity.

• Cross-reactivity testing: Assess potential cross-reactivity with similar proteins through ELISA or other binding assays. This approach has been used for other antibodies, confirming no detectable reactivity with unrelated proteins .

• Immunofluorescence localization: Verify that the antibody staining pattern matches the expected subcellular localization of USP31 in known expressing cell lines, similar to approaches used for UbcH10 antibody validation in hepatoma carcinoma cells .

• Immunohistochemistry with paired samples: Test the antibody on tissues known to express USP31 and those with low/no expression. This approach was effectively used with UbcH10 antibodies on paired HCC paraffin-embedded tissue sections containing tumor tissues and adjacent non-cancerous tissues .

• RNA interference validation: In cell lines expressing USP31, use siRNA or shRNA to knock down expression and confirm reduced antibody staining.

These complementary validation steps provide robust evidence of antibody specificity and should be documented to support experimental reliability.

What is the significance of isotype controls and when should they be used with USP31 antibodies?

Isotype controls are particularly important when working with USP31 antibodies in experiments measuring activation markers or in samples with high non-specific binding potential. Their proper use depends on understanding several key principles:

• For multiparameter experiments (e.g., measuring USP31 alongside activation markers like CD69 or CD25), both Fluorescence Minus One (FMO) controls and isotype controls are necessary .

• Isotype controls work best when the fluorochrome-to-protein (F/P) ratio for the isotype and target antibody are the same, which is achievable when antibodies are purchased from the same company .

• For experiments involving unlabeled primary antibodies, using matching subclass antibodies as isotype controls provides better control as the same fluorescent conjugate is used in both test and control tubes .

• An alternative approach is blocking experiments, where samples are first incubated with unlabeled blocking antibody to block Fc receptors and other non-specific binding sites, then incubated with fluorescently-labeled antibodies .

• For USP31 antibody class characterization, knowledge of class and subclass (e.g., IgG1 with κ light chain) is essential for selecting appropriate isotype controls, similar to how other antibodies are characterized .

Understanding when and how to use isotype controls ensures proper interpretation of results, particularly when investigating subtle expression changes in USP31 levels.

How should I design compensation controls when using USP31 antibodies in multicolor flow cytometry?

Designing proper compensation controls for multicolor flow cytometry experiments involving USP31 antibodies requires careful technical consideration:

• Use single-color compensation tubes with BD Compensation Beads or similar products for each fluorochrome in your panel. These beads provide consistent negative and bright positive populations ideal for accurate compensation calculations .

• The compensation beads approach is particularly valuable for antigens with low density (like potentially USP31 in some cell types) because:

  • Beads have a negative population with consistent background fluorescence

  • They provide a relatively high positive peak that informs researchers that the antibody and fluorochrome are functional under experimental conditions

• If your experimental samples have fluorescence signals higher than what the beads can achieve, use a mixture of highly positive cells and negative beads for more accurate compensation .

• When using annexin V or other non-antibody fluorescent markers alongside USP31 antibodies, create custom compensation controls by binding the reagent to carboxylated beads .

• Compensation settings should be recalculated if antibody lots change, bead lots change, or the instrument undergoes service .

This systematic approach to compensation ensures accurate discrimination between positive and negative populations when analyzing USP31 expression in complex experimental designs.

What is the optimal protocol for immunohistochemical detection of USP31 in tissue samples?

For optimal immunohistochemical detection of USP31 in tissue samples, researchers should follow this methodological approach:

• Sample preparation:

  • Use deparaffinized tissue sections placed in citrate buffer

  • Perform antigen retrieval using microwave heating for 20 minutes

  • For frozen sections, fix with cold paraform prior to immunostaining

• Antibody incubation:

  • Dilute anti-USP31 antibodies to approximately 1:500

  • Incubate sections overnight at 4°C for optimal signal-to-noise ratio

  • After washing in PBS, incubate with HRP-conjugated secondary antibody for 1 hour at room temperature

• Detection and visualization:

  • Perform DAB staining according to manufacturer's protocol

  • Counterstain nuclei if needed for structural context

  • Mount slides with appropriate mounting medium

• Controls to include:

  • Serial sections with isotype control antibody at the same concentration

  • Known positive tissue samples to verify staining protocol

  • Adjacent non-cancerous tissues for comparison when examining potential pathological changes

This protocol has been successfully employed for similar protein detection, yielding specific staining patterns that allow for evaluation of expression levels in both normal and disease tissues.

How can I effectively use USP31 antibodies for protein quantification in research samples?

Effective quantification of USP31 protein using antibody-based techniques requires careful consideration of methodology and controls:

For optimal quantification:

• Always include a standard curve using recombinant USP31 protein when possible, especially for ELISA-based quantification.

• For Western blot quantification, use housekeeping proteins as loading controls (β-actin, GAPDH) and analyze band intensity with image analysis software.

• When analyzing tissues, consider laser capture microdissection to isolate specific cell populations before protein extraction to avoid heterogeneous cell type effects.

• For flow cytometry quantification, use calibration beads with known antibody binding capacity to convert fluorescence intensity to absolute numbers of USP31 molecules per cell.

• Always run technical replicates (minimum triplicate) and biological replicates to ensure statistical significance of any observed differences in USP31 expression levels.

This comprehensive approach ensures accurate and reproducible quantification of USP31 protein levels across different experimental systems and biological contexts.

How can I troubleshoot non-specific binding with USP31 antibodies?

Non-specific binding is a common challenge when working with antibodies like those targeting USP31. Effective troubleshooting approaches include:

• Optimize blocking conditions:

  • Increase blocking reagent concentration (5-10% normal serum or BSA)

  • Extend blocking duration (1-2 hours at room temperature)

  • Consider alternative blocking agents if background persists

• Adjust antibody concentration:

  • Titrate your USP31 antibody to find the optimal concentration

  • Test dilutions ranging from 1:100 to 1:5000 to identify the best signal-to-noise ratio

  • Consider whether the antibody titer in culture medium (1:5120-1:10240 for similar antibodies) affects your optimal dilution

• Modify washing procedures:

  • Increase wash buffer volume and number of wash steps

  • Add detergents (0.1-0.5% Tween-20) to wash buffers to reduce non-specific interactions

  • Extend wash times between antibody incubation steps

• For flow cytometry applications:

  • Use Fc receptor blocking before antibody addition

  • Include FMO controls to properly set gates

  • Consider using compensation beads for single-color controls

• For immunohistochemistry:

  • Use biotin/avidin blocking for tissues with high endogenous biotin

  • Consider tissue-specific autofluorescence quenching reagents for IF applications

  • Test different antigen retrieval methods (e.g., citrate buffer vs. EDTA buffer)

By systematically implementing these approaches, researchers can significantly improve signal specificity when working with USP31 antibodies.

What criteria should be used to assess USP31 antibody quality for research applications?

Rigorous assessment of USP31 antibody quality is essential for reliable research applications. Key quality criteria include:

• Specificity validation:

  • Cross-reactivity testing with similar proteins should show no detectable reactivity with unrelated proteins, similar to validation performed for other antibodies

  • Western blot should show a single band of expected molecular weight

  • Immunoprecipitation followed by mass spectrometry should confirm USP31 as the primary target

• Sensitivity assessment:

  • Limit of detection determination using titrated recombinant USP31 protein

  • Signal-to-noise ratio evaluation across different antibody concentrations

  • Comparison of detection limits across different applications (WB, IHC, IF)

• Reproducibility testing:

  • Lot-to-lot consistency evaluation

  • Intra-assay and inter-assay coefficient of variation calculation

  • Stability assessment after multiple freeze-thaw cycles

• Application-specific performance:

  • Antibody class and subclass characterization (e.g., IgG1 with κ light chain)

  • Titer determination in both culture medium and ascites fluid

  • Evaluation of antibody content in culture medium (μg/ml)

• Batch verification through:

  • ELISA titration curves compared to reference standards

  • Side-by-side testing with previously validated antibody lots

  • Performance in at least two different applications (e.g., WB and IHC)

How can I optimize USP31 antibodies for co-immunoprecipitation experiments to identify interaction partners?

Optimizing co-immunoprecipitation (co-IP) experiments with USP31 antibodies requires careful consideration of several technical factors:

• Antibody selection and preparation:

  • Choose antibodies that recognize native USP31 (not just denatured forms)

  • Test both polyclonal and monoclonal antibodies, as each has advantages

  • Consider covalently coupling the antibody to beads to prevent heavy chain interference in Western blot detection

• Lysis buffer optimization:

  • Use mild non-ionic detergents (0.5-1% NP-40 or 0.5% Triton X-100)

  • Include protease inhibitors and deubiquitinase inhibitors (N-ethylmaleimide)

  • Test different salt concentrations (100-150mM NaCl) to preserve interactions while reducing non-specific binding

• Experimental procedure:

  • Pre-clear lysates with control IgG and protein A/G beads

  • Perform IP with USP31 antibody and matched isotype control in parallel

  • Include a sample of input lysate (5-10%) for comparison

  • Wash beads extensively (4-5 times) with decreasing salt concentrations

• Validation and analysis:

  • Confirm successful IP by Western blotting a portion of the IP for USP31

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting

  • Verify interactions with reciprocal IP using antibodies against interacting proteins

  • Confirm biological relevance of interactions through functional assays

What considerations are important when using USP31 antibodies for studying protein localization changes under different cellular conditions?

When studying USP31 localization changes under different cellular conditions, researchers should consider these important methodological aspects:

• Fixation and permeabilization optimization:

  • Test different fixatives (paraformaldehyde vs. methanol) as they preserve different epitopes

  • Optimize permeabilization conditions (0.1-0.5% Triton X-100 or 0.05-0.2% saponin)

  • Consider dual fixation protocols for simultaneous preservation of membrane and nuclear structures

• Co-localization studies:

  • Use well-characterized markers for cellular compartments (nuclear, cytoplasmic, membrane, etc.)

  • Employ high-resolution imaging techniques (confocal microscopy, STED, or SIM)

  • Quantify co-localization using appropriate software and statistical metrics (Pearson's correlation, Mander's overlap coefficient)

• Live-cell imaging considerations:

  • For tracking dynamic changes, consider fluorescently-tagged USP31 constructs

  • Validate that tagged constructs localize similarly to endogenous USP31 using antibody staining

  • Control for overexpression artifacts by using stable cell lines with near-endogenous expression levels

• Stimulus-response experiments:

  • Document baseline localization before perturbation

  • Perform time-course experiments to capture transient relocalization events

  • Include appropriate controls for each treatment condition

• Quantification approaches:

  • Measure nuclear/cytoplasmic ratios using appropriate image analysis software

  • Assess co-localization with specific organelles or proteins under different conditions

  • Use high-content imaging platforms for analysis of multiple parameters simultaneously

This comprehensive approach ensures accurate characterization of USP31 localization dynamics in response to cellular perturbations, providing insights into its functional regulation.